Bladder cancer: Pioglitazone-when is a prescription drug safe?

Loke, Yoon Kong and Mattishent, Katharina (2015) Bladder cancer: Pioglitazone-when is a prescription drug safe? Nature Reviews Urology, 12. pp. 655-656. ISSN 1759-4812

Full text not available from this repository. (Request a copy)

Abstract

In a recent issue of JAMA, Lewis et al. present long-term data on the likelihood of a link between pioglitazone and the risk of bladder cancer and ten other cancers. Their findings contradict previous concerns regarding the safety of pioglitazone, and add to the controversy surrounding interpretation of rare adverse events associated with prescription drugs.

Item Type:	Article
Uncontrolled Keywords:	bladder cancer,diabetes,drug safety,sdg 3 - good health and well-being ,/dk/atira/pure/sustainabledevelopmentgoals/good_health_and_well_being
Faculty \ School:	Faculty of Medicine and Health Sciences > Norwich Medical School
UEA Research Groups:	Faculty of Medicine and Health Sciences > Research Groups > Health Services and Primary Care Faculty of Medicine and Health Sciences > Research Groups > Health Promotion Faculty of Science > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Groups > Norwich Epidemiology Centre Faculty of Medicine and Health Sciences > Research Centres > Population Health (former - to 2025) Faculty of Medicine and Health Sciences > Research Centres > Mental Health and Social Care (fka Lifespan Health) Faculty of Medicine and Health Sciences > Research Centres > Public Health
Depositing User:	Pure Connector
Date Deposited:	15 Mar 2016 10:11
Last Modified:	30 Jul 2025 09:58
URI:	https://ueaeprints.uea.ac.uk/id/eprint/57468
DOI:	10.1038/nrurol.2015.237

Actions (login required)

View Item